comparemela.com

Latest Breaking News On - Makoto inoue - Page 1 : comparemela.com

ORIX Corporation (NYSE:IX) Q4 2024 Earnings Call Transcript

ORIX Corporation (NYSE:IX) Q4 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

United statesSouth koreaSantoku senpakuKazuki yamamotoMakoto inoueHitomaro yanoEnvironment energyNtt docomoCorporate financial servicesSustainability departmentHigh school graduationOrix corporationO rix corpCall transcript mayInvestor relationsExecutive officer

Japan s Orix to launch buyout fund in asset management pivot, CEO says

TOKYO Japanese finance group Orix will expand its asset management business with a private equity fund, seeing limited earnings growth ahead for its…

Makoto inoueReaking news

TOKYO Japanese finance group Orix will expand its asset management business with a private equity fund, seeing limited earnings growth ahead for it

Makoto inoueJapan s

Otsuka to commercialise hereditary angioedema drug in Europe

Otsuka to commercialise hereditary angioedema drug in Europe
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

United statesMakoto inoueOtsuka pharmaceuticalCalifornia based ionisBrett moniaNorth america

Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema

Otsuka to leverage strong commercial infrastructure and rare disease experience to reach European HAE patientsIonis plans to independently bring donidalorsen to U.S. patients if approvedDonidalorsen.

Makoto inoueOtsuka pharmaceutical co ltdIonis pharmaceuticals incIonis pharmaceuticalsPrnewswire ionis pharmaceuticals incOrphan drug designationHereditary angioedemaConjugated antisenseAllergy organ

vimarsana © 2020. All Rights Reserved.